Cover Image

Three-time-point PET analysis of 68Ga-FAPI-46 in a variety of cancers

A growing family of 68Ga-fibroblast activation protein inhibitor (FAPI) PET probes has shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46, in particular, has emerged as unique for both its diagnostic and its theranostic applications; however, the optimal timing of PET remains unc...

Full description

Saved in:
Bibliographic Details
Main Authors: Naeimi, Mahnoosh (Author) , Choyke, Peter L. (Author) , Dendl, Katharina (Author) , Mori, Yuriko (Author) , Staudinger, Fabian (Author) , Watabe, Tadashi (Author) , Körber, Stefan A. (Author) , Röhrich, Manuel (Author) , Debus, Jürgen (Author) , Kratochwil, Clemens (Author) , Haberkorn, Uwe (Author) , Giesel, Frederik L. (Author)
Format: Article (Journal)
Language:English
Published: April 1, 2023
In: Journal of nuclear medicine
Year: 2023, Volume: 64, Issue: 4, Pages: 618-622
ISSN:2159-662X
DOI:10.2967/jnumed.122.264941
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2967/jnumed.122.264941
Verlag, lizenzpflichtig, Volltext: https://jnm.snmjournals.org/content/64/4/618
Get full text
Author Notes:Mahnoosh Naeimi, Peter L. Choyke, Katharina Dendl, Yuriko Mori, Fabian Staudinger, Tadashi Watabe, Stefan A. Koerber, Manuel Röhrich, Jürgen Debus, Clemens Kratochwil, Uwe Haberkorn, Frederik L. Giesel
Description
Summary:A growing family of 68Ga-fibroblast activation protein inhibitor (FAPI) PET probes has shown promise in imaging a variety of medical conditions. 68Ga-FAPI-46, in particular, has emerged as unique for both its diagnostic and its theranostic applications; however, the optimal timing of PET remains unclear. Therefore, we evaluated uptake at 3 time points after 68Ga-FAPI-46 administration in a spectrum of tumor types. Methods: The cohort consisted of 43 patients with diverse cancer diagnoses undergoing 68Ga-FAPI-46 PET/CT at 3 time points (10 min, 1 h, and 3 h). We determined the tracer uptake based on SUVmean and SUVmax and on tumor-to-background-ratios (TBRs) (SUVmax/SUVmean). Results: There were 171 lesions in the 43 patients. Comparing all lesions at different time points, the mean SUVmax was maximal at 10 min (8.2) and declined slightly at 1 h (8.15) and 3 h (7.6) after tracer administration. Similarly, the mean SUVmax log still had a similar pattern in primary lesions at 10 min, 1 h, and 3 h (n = 30; 0.98, 1.01, and 0.98, respectively), lymph node metastases (n = 37; 0.82, 0.84, and 0.81, respectively), and distant metastases (n = 104; 0.81, 0.79, and 0.74, respectively). TBR also showed nonsignificant differences at the 3 times. Conclusion: 68Ga-FAPI-46 PET/CT imaging revealed remarkably stable tumor and background uptake as determined by SUV metrics and maintained high TBRs within 3 h of injection. Thus, it may be possible to scan with 68Ga-FAPI-46 within 10-20 min of injection, improving workflow and decreasing patient wait times. Confirmation of these findings in a larger cohort is under way.
Item Description:Online veröffentlicht: 3. April 2023
Gesehen am 10.08.2023
Im Titel ist die Zahl 68 hochgestellt
Physical Description:Online Resource
ISSN:2159-662X
DOI:10.2967/jnumed.122.264941

Similar Items